Profile
Robert L.
Kirkman served as President & CEO at Biomira, Inc. and Xcyte Therapies, Inc. before becoming President, CEO & Director at Cascadian Therapeutics LLC, where he worked until 2016.
He also served as Chairman at Trillium Therapeutics ULC and Independent Director at Oncorus, Inc. Additionally, he was VP of Business Development & Corporate Communications at Protein Design Labs, Inc. and briefly served as CFO at Parkway Bank.
Kirkman received his undergraduate degree from Yale University and his doctorate from Harvard Medical School.
Former positions of Robert L. Kirkman
| Companies | Position | End |
|---|---|---|
| ONCORUS, INC. | Director/Board Member | 15/06/2021 |
| TRILLIUM THERAPEUTICS | Chairman | 27/04/2021 |
| CASCADIAN THERAPEUTICS INC (USA) | Chief Executive Officer | 10/01/2016 |
| PARKWAY B | Director of Finance/CFO | 14/07/2008 |
Biomira, Inc.
 Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | President | 10/12/2007 |
Training of Robert L. Kirkman
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ONCORUS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
| Xcyte Therapies, Inc. | Health Technology |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Health Services |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Parkway Bank (Lenoir, North Carolina)
 Parkway Bank (Lenoir, North Carolina) Regional BanksFinance Parkway Bank engages in the provision of commercial banking services. It offers checking and savings accounts, mortgage lending, and deposits. The company was founded on August 9, 2001 and is headquartered in Lenoir, NC. | Finance |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Robert L. Kirkman
